Fischesser Ryan 4

4 · Caribou Biosciences, Inc. · Filed Dec 21, 2021

Form 4

Period: 2021-12-20

VP of Finance and Controller

Transactions

Purchase
Common Stock
2021-12-20$2.69/sh+1,136$3,056→ 101,695 total
Award
Option to purchase Common Stock
2021-12-20+40,000→ 40,000 total
Exercise: $15.16Exp: 2031-12-19→ Common Stock (40,000 underlying)
Exercise of In-Money
Option to purchase Common Stock
2021-12-20−1,136→ 7,384 total
Exercise: $2.69Exp: 2029-03-18→ Common Stock (1,136 underlying)

Footnotes (4)

[F1]These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below.
[F2]The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021.
[F3]The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
[F4]The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Documents

1 file